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ABSTRACT 
This review summarises information on drug products Somatostatin Analogues (SSAs), which are included in the algorithm of Neuroendocrine 
Tumors (NET) treatment. SSAs are the current standard for safe and effective management of NET symptoms and control of tumours growth and 
are administered in a range of dosage forms for parenteral administration, such as intramuscular, subcutaneous and implant. A search criterion was 
the therapy of NET with medicines from a group of SSAs. Literature survey has been done in a range of years 1990-2018 to make the review 
updated and comprehensive and to show the development of SSAs new pharmaceutical dosage forms to improve patient quality of life and side 
effects decrease. The sources were world-recognized journals. Keywords used as filters were NET, SSAs, octreotide, lanreotide, pasireotide, 
Somatostatin Receptors (SSTR), dosage form. The current review is created with an intended to focus on the advantage of SSAs modern dosage 
forms. Literature survey revealed that many studies were carried out to SSAs encapsulation into microspheres that changes the drug bioavailability 
and allows reducing the number of administration. Also, SSAs delivery systems in particular devices such as auto-injector have been created to 
control the continuous concentration of the drug and to provide safety guarantee. Besides, studies have been carried out to prepare SSAs 
formulations for oral administration to improve the quality of life of the NET patients. In this review, SSAs pharmaceutical dosage forms with 
improved pharmacokinetic and therapeutic characteristics and routes of administration are analyzed. 
Keywords: Neuroendocrine tumours, Somatostatin analogues, Dosage form of prolonged-release, Oral administration 
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INTRODUCTION 
Neuroendocrine Tumours (NET) are a rare disease which occurs in 
less than 1% of the population [1]. NET is characterised by the 
presence of secondary symptoms, which are caused by 
hypersecretion of metabolically active substances-biogenic amines 
and regulatory peptide hormones [2]. 
Somatostatin Analogues (SSAs) have a special place in the treatment 
of NET. Medicines of this class not arrest only clinical symptoms and 
reduce the level of tumour biochemical markers but also have 
antiproliferative activity [3-6]. These days SSAs are the current 
standard for safe and effective management of gastropancreatic NET 
symptoms [7-9]. These drugs are the treatment of choice for control 
of tumours growth in patients with inoperable NET [10, 11]. 
Natural somatostatin is synthesised in many tissues, including the 
central and peripheral nervous system, hypothalamus, pancreatic 
islet cells (D-cells), glandular and neuronal cells of the stomach and 
intestine [7, 12]. Somatostatin controls many physiological 
functions: neurotransmission, smooth muscles contractility, stomach 
and intestinal motor functions and nutrient absorption. It reduces 
the growth of neuroendocrine neoplasms, inhibiting proliferation 
and angiogenesis of tumour cells, as well as inducing apoptosis [13]. 
Somatostatin was first isolated in 1973 by French researchers but, 
despite the high biological activity, it never became a drug product. 
Natural somatostatin cannot be used as a drug due to its very short 
half-life in blood plasma (not more than 3 min).  
Already in 1974, the pharmaceutical company Sandoz GmbH, 
Germany, initiated a project to obtain long-acting synthetic 
analogues with a higher activity vs native somatostatin. Later, SSAs 
were created, which proved to be more resistant to enzymatic 
decomposition and possessed improved pharmacokinetic and 
therapeutic characteristics [14, 15]. 
To prepare this review search criterion was the therapy of NET with 
medicines from the group of SSAs. Literature survey has been done 
in a range of years 1990-2018 to make the review updated and 
comprehensive and to show the development of SSAs new 
pharmaceutical dosage forms to improve patient quality of life and 
side effects decrease. The sources were world-recognized journals. 
Keywords used as filter were NET, SSAs, octreotide, lanreotide, 
pasireotide, Somatostatin Receptors (SSTR), dosage form.  
Octreotide–SSA of the first generation 
The first and most studied SSA is octreotide (INN), which is 
characterised by more than 30 y of practical active and safe use 
[16, 17]. 
Octreotide is the synthetic cyclic octapeptide. It has similar to 
somatostatin profile of pharmacological activity but is more 
biologically active due to significantly longer half-life (about 10 min) 
[18]. The group of octreotide containing medicines includes 
immediate-release and long-acting dosage forms. Solutions for 
injections or infusions represent “short-acting” drugs, and dosage 
forms of prolonged action are lyophilised microspheres for 
suspension for intramuscular administration. It should be noted that 
short-acting and long-acting drug products do not show cross-
resistance and can be successfully replaced by each other [19]. 
Initially, octreotide was synthesised as a drug product of immediate 
release administered 2-3 times a day. Octreotide for injection is a 
transparent, colourless sterile solution of octreotide acetate for 
intravenous or subcutaneous administration with the concentration 
of 0.05 to 0.6 mg/ml in ampoules or 1 ml bottles or multidose vials 
containing 5 ml of 0.2 mg/ml or 1 mg/ml solution. The drug is also 
produced in pre-filled disposable syringes (trade name–Serakstal, 
Italfarmaco, Italy). Each ampoule of octreotide solution contains 
excipients: lactic acid, mannitol, sodium bicarbonate and water for 
injection. Lactic acid and sodium bicarbonate are added to produce a 
buffering solution with a pH of 4.2±0.3. Multidose vials also include 
5 mg of phenol per ml as the preservative. 
Octreotide solution is used in acute conditions, such as bleeding 
ulcer. It is not suitable for long-term treatment of NET due to the 
need for frequent injections (3-4 times a day). These days 
biotherapy of NET uses long-acting octreotide in the depot-forms 
(LAR), administering intramuscularly once per month [19]. 
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Octreotide depot-forms  
The most studied and widely used long-acting SSA is Sandostatin® 
LAR, Novartis Pharma AG, Switzerland [7]. It has advantages over 
short-acting octreotide due to the ability to maintain a continuous 
concentration of the drug in the body, which increases the 
symptomatic and antitumour effects. 
Sandostatin® LAR is a powder for suspension for intramuscular 
injections. It contains octreotide, encapsulated and evenly 
distributed inside microspheres made of lactic and glycolic acids 
copolymer and D-(+)-glucose (PLGA D-(+) glucose). Encapsulation of 
octreotide into unique microspheres determines its 
pharmacokinetics profile so that the number of injections is reduced 
from 3 per day to 1 per month. The gradual slow release of 
octreotide occurs during biodegradation of the polymer, especially 
with its hydrolysis. The polymer has an average molecular mass of 
about ~52 kDa, the average diameter of microspheres is 
approximately 50 microns. The bottle with the drug is accompanied 
by a compound solvent, in a pre-filled disposable syringe. When 
mixing lyophilised microspheres with solvent, the suspension is 
formed. The solvent contains sodium carboxymethyl cellulose, 
mannitol, poloxamer 188 and water for injection and is a 
transparent solution from colourless to light yellow or brown colour. 
Mannitol is added to the dosage form to improve suspending. The 
resuspending of the drug is carried out upon cooling and involves 
seven different stages, including a very delicate shaking to obtain a 
homogeneous suspension before administration. The disadvantages 
of the product include a complicated procedure of drug preparation 
for administration, extreme pain after intramuscular injection with a 
long thick needle and the prolonged duration of the dose due to the 
high viscosity of the suspension. 
The new depot form of the octreotide for subcutaneous 
administration (Novartis Pharma AG, Switzerland) was developed 
using FluidCrystal® technology (Camurus AB, Lund, Sweden) to 
remove the above restrictions for Sandostatin® LAR. The name of 
the drug is Octreotide FluidCrystal® Product CAM2029. It is a ready-
to-use prolonged dosage form of octreotide, expected to be 
marketed in pre-filled syringes (product can be injected by patients 
independently with auto-injector). It is intended for subcutaneous 
injection through a thin needle (22-27 G). A biodegradable liquid 
crystal gel is formed at the site of injection by the administration of a 
small volume of liquid. The liquid-crystal phase formulation is a 
spontaneous process, which is the result of the lipids self-
aggregation, which begins immediately after injection. Immediate 
start of gel formulation leads to the effective release of the active 
substance from depot matrix, providing rapid (“burst”) initial 
release (without opening), follows by a slower and stable stage of 
the drug release. 
Phase I and II comparative clinical trials of octreotide-depot 
subcutaneous administration and Sandostatin® LAR showed that the 
octreotide-depot injected subcutaneously, has a satisfactory safety 
profile. It is similar to that of the prolonged octreotide dosage form and 
corresponds to Sandostatin® LAR in terms of the duration of the 
therapeutic effect. The clear advantages of octreotide-depot 
subcutaneous are five times higher bioavailability, which allows effective 
control of symptoms in patients with functioning NET, and convenience 
of drug application by patients and medical personnel [20-22]. 
The pharmaceutical company Endo Pharmaceuticals, Ireland, also 
attempted to create a prolonged-release dosage form of octreotide. This 
company has developed a pharmaceutical composition for subcutaneous 
administration as an implant. The drug is octreotide enclosed in a 
polyurethane/methacrylate hydrophilic polymer, releasing 30 to 800 μg 
of active substance per day for six months in vivo. The hydrophilic 
polymer additionally contains the releasing agent Brij 35 
(polyoxyethylene lauryl ether), polyoxyethylene (20) sorbitan trioleate, 
tween 20, tween 80, vitamin E TPGS and/or their mixtures. The dose of 
octreotide in the implant is from 40 to 120 μg [23]. 
Phase II and III clinical trials have demonstrated the safety and 
efficacy of octreotide-implant in patients who previously used 
Sandostatin® LAR. Advanced studies have shown that biochemical 
parameters and safety profiles remain unchanged for more than 24 
w [24, 25]. 
Lanreotide and its long-acting dosage forms  
Another SSA, actively used in clinical practice, is lanreotide. 
Lanreotide is a cyclic octapeptide containing D-tryptophan inside 
the ring, which stabilizes the molecule. N-end D-alanine increases 
the selectivity of the drug. Advanced researches have established 
that lanreotide provides 85 times higher antisecretory effect than 
that of native somatostatin [26]. 
The drug is used in two long-acting dosage forms–Somatuline® and 
Somatuline® Autogel® (Ipsen Pharma, France). 
Somatuline® is a lyophilisate for suspension for intramuscular 
injection. Just as in Sandostatin® LAR, in this dosage form lanreotide 
is enclosed in microspheres of the copolymer of lactic and glycolic 
acids. The gradual release of lanreotide from microspheres causes 
prolonged (up to 10-14 d) presence of the drug in the blood. At the 
same time, the pharmacological efficacy of the drug can be adjusted 
by changing the duration of time between injections: 7, 10 or 14 d 
[27]. The vial with lyophilisate is provided with the ampoule with 
solvent (0.8% mannitol solution) to disperse in it to form a 
suspension of the white or off-white colour. 
Octreotide and lanreotide depot-forms obtained by 
microencapsulation have shown efficacy in the treatment of NET. 
But nowadays such dosage forms are considered first-generation 
drugs due to many of medical disadvantages: the need to dissolve 
before administration, the probability of step-like or even “burst” 
release of the active substance, the formation of acid (acidic) 
metabolites in the process of polymer degradation and possible 
degradation of peptide [28, 29]. Technological process of these 
dosage forms is rather complicated and often requires the use of 
organic solvents, which are toxic [30]. 
Besides, intramuscular injections of these drugs are often painful; 
the need of administration of large volume leads to a limitation of 
the amount of a single drug administered and, therefore, leads to 
reducing the time between injections and consequently reducing 
patient’s quality of life. All these factors required the development of 
a new dosage form of lanreotide with an improved pharmacokinetic 
profile and free of the above disadvantages. 
In the process of such dosage form development, it was found that 
under certain conditions lanreotide in an aqueous solution forms a 
gel without the use of excipients or additional procedures [31-37]. 
At first, lanreotide as a cyclic octapeptide forms noncovalent dimers. 
They joined into filaments (fibres) stabilized by hydrogen bonds. 
Twenty-six filaments form a hollow nanotube of uniform diameter 
equal to 24 nm. The structure of the soft gel depends on lanreotide 
concentration: at 10-15% nanotubes in the soft gel can be organized 
into a hexagonal crystal lattice. At higher lanreotide levels, the 
densely packed tube with nanotubes inside begins to form. 
Noncovalent hydrogen bonds between dimer subunits, hydrophobic 
interactions and π-π staking of aromatic side chains inside threads 
stabilize nanotubes [35, 38]. 
Such interactions can be formed and exist in water and do not 
require the presence of any excipients. In vitro experiments have 
shown that the formation of such nanotubes is reversible: at low 
concentrations of lanreotide, nanotubes slowly “disassemble”, 
releasing the active substance in a slow and controlled manner 
immediately after transfer to the diluted solution [39]. The drug 
product was called Somatuline® Autogel®. 
It is recognized that in vivo Somatuline® Autogel® forms a depot at 
the site of injection when the dosage form interacts with 
physiological fluids. Lanreotide peptide properties regulate the 
release of the active substance. Likely it occurs due to passive 
diffusion of lanreotide from the depot into surrounding tissues with 
subsequent absorption into the blood [39]. 
Indeed, clinical trials of drug pharmacokinetics confirmed that after 
subcutaneous injections Somatuline® Autogel® forms a depot with 
high concentrations of the drug within one day, followed by a 
controlled and prolonged release of the drug over a significant time 
[40]. Thus, in NET patients receiving a dose of 120 mg of lanreotide-
depot every four weeks, the plateau of drug concentration in the 
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blood serum was reached after four or five injections with a level of 
5.3 to 8.6 ng/ml. Pharmacokinetic characteristics of lanreotide depot 
form allow using the drug at an interval of 4 w. 
The depot form of lanreotide has other significant advantages: the 
preparation is ready to use; it is packed in a pre-filled device, which 
eliminates the need for a multi-stage process of solution preparation. 
Subcutaneous injections of the drug in small volume can be carried out 
by individuals without specialized medical training. 
Also, the new design of the lanreotide syringe for injection provides 
an additional safety guarantee. It has a protective device that 
automatically retracts and blocks the needle after use, thus 
preventing from accidental puncture after injection. The syringe is 
transparent, and after full release of content, a click occurs, which 
allows controlling the administration of the drug. That is, the use of 
Somatuline® Autogel® allows achieving tumour control without 
impairing the quality of life of the patient [41-43]. 
Pasireotide–SSA with universal binding profile 
It is well-known that SSAs exhibit direct antitumor activity through 
binding with SSTR, subtypes 1-5 expressed in neuroendocrine tumor 
cells [44]. Octreotide and lanreotide have an affinity to subtype two 
receptors (SSTR2), moderately bind to subtype five receptors 
(SSTR5), very weakly bind to SSTR3 and have little binding to SSTR1 
and SSTR4 [45]. 
The concept of a metabolically stable SSA with the universal binding 
profile is realized in the cyclic hexapeptide–pasireotide (SOM 230, 
Signifor®). Pasireotide has a high affinity to SSTR1, SSTR2, SSTR3 
and SSTR5 receptors. Pasireotide affinity to SSTR1, SSTR3 and 
SSTR5 is 30, 11 and 158 times more top than that of Octreotide, 
respectively [46, 47]. 
Non-clinical investigations have shown that pasireotide inhibits the 
growth of NET in vitro significantly than octreotide [48]. Besides, the 
unique binding profile of pasireotide to receptors allows using it in 
patients with disseminated NET, refractory or resistant to 
octreotide/lanreotide. Pasireotide also can be used for the treatment of 
other tumours in which types SSTR2 and SSTR5 are relevant [49-51]. 
Initially, pasireotide dosage form contained 3 ml of solution with an 
active substance concentration of 0.05 mg/ml or 1.0 mg/ml in vials. 
According to the results of phase I clinical trials, the dosage form of 
pasireotide was optimized. The drug registered in the USA, EU and 
Russia (Signifor®, Novartis Pharma AG, Switzerland) is a solution of 
pasireotide diaspartate for injection with a concentration of 
0.3 mg/ml, 0.6 mg/ml or 0.9 mg/ml in 1 ml glass ampoules. In 
addition to the active substance, the drug contains mannitol as a 
regulator of the tonicity of the solution, tartaric acid as a buffering 
agent, sodium hydroxide to regulate pH and water for injection as a 
solvent. The product is recommended for subcutaneous 
administration twice a day. 
Pasireotide prolonged-release dosage form (Signifor® LAR, Novartis 
Pharma AG, Switzerland) is a powder for suspension for injection in 
a vial that should be suspended in the supplied solvent immediately 
before application. The active substance of Signifor® LAR is 
pasireotide pamoate (or embonate). Unlike pasireotide diaspartate, 
it is practically insoluble in water and buffer solutions with a pH 
below 4.0 and demonstrates high stability in the selected controlled-
release polymer system. In the prolonged-release dosage form, 
pasireotide pamoate (10, 20 mg, 30, 40 mg or 60 mg) is evenly 
distributed among biodegradable microspheres based on poly-D, L-
lactide-co-glycolide (PLGA). Both copolymers belong to the well-
known family of biocompatible poly (D, L-lactide-co-glycolide) 
copolymers, which are used for many years in similar commercial 
drugs [52-54]. They consist of lactide and glycolide, which are 
forming blocks, and degraded to lactic and glycolic acids, 
physiological to the body and metabolized by normal physiological 
pathways, and suitable for use in humans for parenteral 
administration. The active substance is gradually released from 
microspheres, primarily through diffusion and hydrolysis/ 
degradation. It is assumed that with the slow pasireotide release 
from the dosage form, its concentration will not fluctuate 
significantly, which will allow minimizing side effects. During non-
clinical researches and phase I clinical trials different variants of 
copolymers compositions, their ratio and manufacturing processes 
were developed and tested. The proposed formulation has been 
chosen as having the most favorable pharmacokinetic profile [55]. 
The drug is packed in a blister containing pasireotide in the ampule 
and a solvent filled syringe, and adapter for the vial and a special 
needle for safe injection. The solvent consists of sodium carmellose, 
mannitol, poloxamer 188 and water for injection. It looks like a 
transparent solution of light yellow or light brown colour. The 
decision of solvent (selection of excipients, manufacturing process 
and choice of container closure system) is based on Novartis Pharma 
AG’s previous experience in the development of medicines in 
microspheres [56].  
Signifor® LAR is administered intramuscularly once every 28 d. 
Clinical trials have shown that the use of pasireotide prolonged-
release dosage form allows achieving better control over the disease 
vs standard SSAs therapy-Sandostatin® LAR and Somatuline® 
Autogel® [57]. 
Vapreotide 
Vapreotide (Octastatin®, Sanvar®, RC 160, BMY 41606) is a 
synthetic cyclic octapeptide, developed in Tulane University School 
of Medicine, USA [58]. Vapreotide exhibits an affinity to SSTR2 
receptors and a lesser extent to SSTR5. As for other SSAs, the direct 
and indirect effect of vapreotide is manifested through the inhibition 
of release of the somatotropic hormone and other peptides. 
According to the non-clinical studies and clinical trials data, 
vapreotide has higher metabolic stability compared to other known 
SAS-it is the only SSA that remains stable for an extended time at 
room temperature. The therapeutic potential of vapreotide, 
however, is limited due to a short half-life. 
Vapreotide is usually administered subcutaneously in the immediate-
release dosage form. A prolonged-release dosage form for intramuscular 
administration is also available. Other prolonged-release dosage forms 
are in the pharmaceutical development stage [59]. Sanvar® (H3 Pharma 
Inc., Canada), slow-release product (600 µg of vapreotide) has 
demonstrated statistically significant benefits of early use in clinical trials 
in the treatment of acute oesophagal variceal bleeding. Currently, phase 
III clinical trials are ongoing [60]. 
SSAs dosage forms for oral administration 
The information provided above indicates that SSAs are 
manufactured in dosage forms for parenteral use for 
intramuscular/subcutaneous administration. Physical and chemical 
properties of active substances (large size of molecules, the 
tendency to aggregation, adsorption and denaturation) limit the 
development and application of dosage forms for oral use [61, 62]. 
Also, oral use of SSAs as peptides is characterized by low and 
variable systemic bioavailability due to the possibility of enzymatic 
decomposition in the gastrointestinal tract, inability to cross the 
epithelial barrier of the small intestine and short half-life time in 
blood plasma [63, 64].  
Researchers from different countries have repeatedly made 
attempts to increase intestinal absorption of octreotide to create its 
oral dosage form, but none of them was commercially successful 
[65-67]. 
However, recently, Chiasma, Inc., USA, developed a new dosage form 
of octreotide (Octreolin™), which is octreotide acetate in capsules for 
oral use. An innovative patented technology called Transient 
Permeability Enhancer (TPE®) is used for the manufacture of the 
drug product. It facilitates the gastrointestinal absorption of 
unmodified octreotide into the bloodstream. The dosage form 
manufactured by this technology is gastro-resistant capsules filled 
with a water-in-oil suspension of drug and sodium caprylate in 
hydrophilic microparticles, which are placed into lipophilic medium 
to increase intestinal permeability [68]. The drug creators claim that 
the TPE® system (primarily sodium caprylate) increases the 
bioavailability of octreotide after oral administration inducing the 
temporary and reversible opening of jejunal epithelial tight 
junctions. Improved paracellular absorption of the peptide through 
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the wall of the small intestine provides its active entry into the 
systemic bloodstream in the unchanged native active form. On the 
other hand, TPE® technology protects the drug molecule from the 
aggressive effects of the gastrointestinal environment. In non-
clinical studies, it was shown that intestinal absorption of octreotide 
is dose-dependent, and drug effect on the somatotropin hormone is 
comparable to the action of the injectable form of octreotide [69]. 
Phase I clinical trials demonstrated safety and satisfactory 
tolerability of the drug and the absence of severe side effects. It was 
shown that pharmacokinetic profiles of the drug are identical after 
single oral and subcutaneous injection [70]. Phase III clinical trial of 
Octreolin™ conducted by Chiasma together with Roche 
(Switzerland) demonstrated the efficacy of the drug in control the 
activity of insulin-like growth factor and somatotropic hormone in 
patients transferred from registered injectable SSAs. The studies 
showed that Octreolin™ safety profile does not differ from that of the 
approved injectable SSAs. However, the study noted the effect of 
food products on the efficacy of the drug. Also, drug interactions 
were observed: the use of Octreolin™ capsules after meals or with 
proton pump inhibitors, such as esomeprazole, led to the changes of 
gastric pH, significantly affecting oral absorption of the peptide [71]. 
Aegis Therapeutics LLC, USA, also attempted to create a dosage form 
of octreotide for oral use. E. Maggio and P. Grasso studied the 
bioavailability of octreotide acetate dissolved in Intravail® (a 
registered alkyl saccharide, a compound that improves transmucosal 
absorption). The results of a comparative pharmacokinetic study 
showed that oral administration of this dosage form is sufficient. It 
significantly increases total absorption (1254.08 ng/ml/min vs 
311.63 ng/ml/min, respectively), bioavailability (4.0 vs 1.0) and 
serum half-life (52.1 min vs 1.3 min), as compared to subcutaneous 
administration. Thus, oral administration of octreotide in the form of 
Intravail® is a new practical approach for non-invasive treatment of 
NET [72]. 
Cyphetrylin–SSA, worked out in Russia  
At the N. N. Blokhin National Medical Research Center of Oncology 
investigators worked on the synthesis of SSAs (including cytotoxic) 
for many years, and also the investigation of antitumour activity of 
the obtained compounds was carried out [73, 74]. 
Cyphetrylin, which is a noncyclic pentapeptide, SSA, showed a 
pronounced antitumour activity in vitro and in vivo [75]. Due to the 
protection of the reactive side-chain groups with 
tretbutyloxycarbonylic, benzyloxycarbonylic and tetrahydropyran 
groups, Cyphetrylin is metabolically resistant in the acidic 
environment of the stomach which allows developing a dosage form 
of the drug for oral use [76, 77]. 
 
 
Fig. 1: Structural formula of Cyphetrylin 
 
Non-clinical studies of Cyphetrylin dosage form models showed that 
oral administration allows maximizing its antitumour effect: the 
drug inhibits the growth of experimental tumours by 83-90% with a 
statistically significant therapeutic effect during three weeks [78]. 
Non-clinical studies of Cyphetrylin tablets pharmacokinetics showed 
the availability of Cyphetrylin for all studied organs and tissues, 
including brain and tumour [79]. And the results of non-clinical 
safety studies allowed to determine the initial (starting) safe dose 
for humans for phase I clinical trials [80]. 
CONCLUSION 
SSAs play an essential role in drug therapy of NET. It follows from the 
above that the researches in this group of medicines are focused on 
prolonged therapeutic effect of drugs to reduce the number of 
administration. The development of dosage forms for oral 
administration makes it possible to proceed to non-invasive treatment of 
NET. Thus, achievements in the development of innovative dosage forms 
of SSAs not only significantly simplify the therapy of patients with NET, 
but dramatically increase the quality of life of such patients. 
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